2500% Increase in Stem Cell Clinical Trials for Coronavirus, with Ritter Pharmaceuticals (RTTR) among those Sharing an Interest in Stem Cell Research.


A new report out shows that Bio-Pharm companies have shifted their focus from CX pathology systems (what has typically been for Coronovirus) to research on the effect of Stem Cell differentiation on the Corona Virus.

Previously, there was a total of Three new clinical studies  on Clinicaltrials.gov investigating the potential of stem cells to help patients infected with the new coronavirus 2019-nCoV. However, as of March 1, there has been a record 80 or more new clinical trials to tackle the new viral illness. That number is likely to go over 100 soon within the first week of March. This represents a 2500% increase in Stem Cell clinical trials due to the new shift in combating the coronavirus threat.

In Beijing, they have already begun a major Stem Cell clinical trial aimed to combat the virus, with a significant amount of funding supporting its trial.

The 2019 novel coronavirus (2019-nCoV) infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. There is no confirmed antivirus therapy for people infected 2019-nCoV, most of them should receive supportive care to help relieve symptoms. For severe cases, treatment should include care to support vital organ functions. This clinical trial is to inspect the safety and efficiency of Mesenchymal Stem Cells (MSCs) therapy for pneumonia patients infected with 2019-nCoV.


Ritter Pharmaceuticals Inc. (RTTR) appears to already immersed in the Stem Cell domain with RTTR Director Paul V. Maier, who is now listed as an independent director on the board of the International Stem Cell Corp. International Stem Cell Corporation (ISCO) is a publicly traded clinical stage biotechnology company with a powerful new stem cell technology called human parthenogenetic activation that promises to significantly advance the field of regenerative medicine.

Coming before the announced merger with Qualigen, Inc.

“The time is right for us to take advantage of our core science and regulatory experience from our diagnostic business and expand into promising cancer therapeutic drugs and devices,” said Michael S. Poirier, President, Chief Executive Officer and Chairman of Qualigen. “With this transaction and our key knowledge in cancer and infectious disease, we look forward to progressing our clinical development programs.”


Other Stem Cell companies are currently under the radar of investors, such as StemSation International (STSN), who as of last week launched a new Stem Cell product.

Dr. Mira Gadzala of StemSation International commented,

“We are excited to offer this gold-standard, innovative StemRCM product that supports health and wellness and anti-aging processes in multidimensional ways by rejuvenating the cells and stem cell function, strongly supporting the immune system and immunomodulatory responses, activating and nourishing vital bio-molecular pathways and telomere health, and increasing cellular energy processes. The novel combination of apigenin – a powerful and unique antioxidant from green parsley, with other highly effective compounds that come from the most potent natural sources helps to protect our health and promote healthy longevity in synergistic ways. We believe that StemRCM offers new solutions for health & wellness and vibrant longevity.”

Source: https://www.globenewswire.com/news-release/2020/02/18/1986261/0/en/StemSation-Launches-Flagship-Product-StemRCM.html

https://www.nasdaq.com/market-activity/stocks/stsn

Leave a Reply

Your email address will not be published. Required fields are marked *